Prolonged neurophysiologic effects of levetiracetam after oral administration in humans

Epilepsia

Volumn 49, Issue 7, 2008, Pages 1169-1173

  Epstein, Charles M ^a,b   Girard Siqueira, Lhys ^a   Ehrenberg, Joshua Andrew ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

Author keywords

Drug half life; Levetiracetam; Pharmacodynamics; Transcranial magnetic stimulation

Indexed keywords

ETIRACETAM;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MOTOR PERFORMANCE; NEUROPHYSIOLOGY; NEUROTOXICITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; TRANSCRANIAL MAGNETIC STIMULATION; UNSTEADINESS; VISUAL ANALOG SCALE; VOLUNTEER;

ADULT; ANTICONVULSANTS; BRAIN; FEMALE; HALF-LIFE; HUMANS; INTRACELLULAR SPACE; MALE; MIDDLE AGED; PIRACETAM; PSYCHOMOTOR PERFORMANCE; RECEPTORS, PRESYNAPTIC; SYNAPSES; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 47249119209     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01562.x     Document Type: Article

References (14)

1. Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L 2005) The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate- dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 313 : 720 730.
2. Epstein C, Davey K 2002) Iron-core coils for transcranial magnetic stimulation. J Clin Neurophysiol 19 : 376 381.
3. Gillard M, Chatelain P, Fuks B 2006) Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 24 : 102 108.
4. Lukyanetz EA, Shkryl VM, Kostyuk PG 2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 : 9 18.
5. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ 2003) Reduction of voltage operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45 : 661 671.
6. Mishory A, Molnar C, Koola J, Li X, Kozel FA, Myrick H, Stroud Z, Nahas Z, George MS 2004) The maximum-likelihood strategy for determining transcranial magnetic stimulation motor threshold: using parameter estimation by sequential testing is faster than conventional methods with similar precision. J ECT 20 : 160 165.
7. Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F 2007) The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 48 : 1842 1849.
8. Radtke RA. (2001) Pharmacokinetics of levetiracetam. Epilepsia 42 (Suppl 4 24 27.
9. Rambeck B, Jürgens UH, May TW, Pannek HW, Behne F, Ebner A, Gorji A, Straub H, Speckmann E-J, Pohlmann-Eden B, Löscher W 2006) Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 47 : 681 694.
10. Reis J, Wentrup A, Hamer HM, Mueller HH, Knake S, Tergau F, Oertel WH, Rosenow F 2004) Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function - a TMS study. Epilepsy Res 62 : 41 51.
11. Sohn YH, Kaelin-Lang A, Jung HY, Hallett M 2001) Effect of levetiracetam on human corticospinal excitability. Neurology 57 : 858 863.
12. Tong X, Patsalos PN 2001) A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 133 : 867 874.
13. Yang XF, Weisenfeld A, Rothman SM 2007) Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 48 : 1861 1869.
14. Ziemann U, Steinhoff BJ, Tergau F, Paulus W 1998) Transcranial magnetic stimulation: its current role in epilepsy research. Epilepsy Res 30 : 11 30.